Vanguard Group Inc. Acquires 211,960 Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Vanguard Group Inc. increased its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.3% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 16,649,126 shares of the biopharmaceutical company’s stock after purchasing an additional 211,960 shares during the period. Vanguard Group Inc. owned 7.43% of Alexion Pharmaceuticals worth $2,180,703,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of the stock. Steward Partners Investment Advisory LLC bought a new stake in shares of Alexion Pharmaceuticals during the second quarter worth approximately $28,000. Redhawk Wealth Advisors Inc. bought a new stake in shares of Alexion Pharmaceuticals during the second quarter worth approximately $29,000. Ossiam bought a new stake in shares of Alexion Pharmaceuticals during the second quarter worth approximately $32,000. Thor Advisors LLC bought a new stake in shares of Alexion Pharmaceuticals during the first quarter worth approximately $34,000. Finally, NEXT Financial Group Inc bought a new stake in shares of Alexion Pharmaceuticals during the second quarter worth approximately $36,000. Institutional investors and hedge funds own 93.13% of the company’s stock.

In other Alexion Pharmaceuticals news, EVP Indrani Lall Franchini sold 4,500 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $132.78, for a total transaction of $597,510.00. Following the completion of the transaction, the executive vice president now directly owns 29,627 shares in the company, valued at $3,933,873.06. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.08% of the stock is owned by insiders.

A number of equities research analysts have recently issued reports on the company. Citigroup set a $150.00 price objective on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 30th. Morgan Stanley set a $177.00 price objective on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 21st. BMO Capital Markets assumed coverage on Alexion Pharmaceuticals in a report on Thursday, September 12th. They set an “outperform” rating and a $149.00 price objective for the company. ValuEngine cut Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, August 8th. Finally, Stifel Nicolaus restated a “hold” rating on shares of Alexion Pharmaceuticals in a report on Friday, August 30th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company’s stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $160.44.

Shares of NASDAQ ALXN traded up $1.20 during midday trading on Friday, reaching $106.87. The company’s stock had a trading volume of 47,591 shares, compared to its average volume of 3,209,523. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.56 and a current ratio of 4.04. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $92.56 and a fifty-two week high of $141.86. The business’s 50 day moving average price is $108.90 and its two-hundred day moving average price is $123.69. The company has a market cap of $23.73 billion, a P/E ratio of 14.98, a P/E/G ratio of 1.02 and a beta of 1.67.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.13 by $0.51. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. The company had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same period in the previous year, the business earned $2.07 earnings per share. The firm’s quarterly revenue was up 15.1% on a year-over-year basis. Sell-side analysts forecast that Alexion Pharmaceuticals, Inc. will post 9.03 earnings per share for the current fiscal year.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

See Also: Swap

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.